A dual role of AcSDKP in chronic kidney disease: Targeting pericyte-driven fibrosis and vascular repair via VEGF/FGFR1 while eliciting a compensatory FGFR1 upregulation in apoptotic tubular cells
PLOS One · 2026
DOI: 10.1371/journal.pone.0355409 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Shiyi Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Kidney Pathology and Immunology Laboratory, Pediatric Clinical Research Institute of Soochow University, Pediatric Clinical Medical College of Soocho…. Hauptthemen laut MEDLINE: Pericytes, Vascular Endothelial Growth Factor A, Receptor, Fibroblast Growth Factor, Type 1, Renal Insufficiency, Chronic. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Suzhou Key Discipline Project of Pediatric Immunology, Key Laboratory in Science and Technology Development Project of Suzhou.
Abstract (Originalsprache)
Background
Renal interstitial fibrosis and peritubular capillary (PTC) rarefaction drive the progression of chronic kidney disease (CKD). While N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is an endogenous anti-fibrotic peptide, its specific effects on pericyte-endothelial crosstalk and tubular epithelial survival remain controversial.
Methods
We employed a self-controlled unilateral aristolochic acid (AA)-induced CKD mouse model to evaluate the time-sensitive efficacy of AcSDKP. In vitro, primary murine pericytes, human tubular epithelial cells (HK-2), and endothelial cells were utilized. Functional mechanisms were dissected using VEGF ELISA, RNA-sequencing, and targeted FGFR1 siRNA knockdown.
Results
In vitro, AcSDKP potently suppressed TGF-β1-induced pericyte-to-myofibroblast transition (PMT) and robustly restored pericyte-derived VEGF secretion, thereby rescuing endothelial tubulogenesis. In vivo, early AcSDKP intervention (Week 3) significantly mitigated fibrosis, preserved capillary integrity, and improved systemic renal function (BUN/SCr), whereas late intervention (Week 4) was less effective. Transcriptomics identified the VEGF/FGFR1 axis as a primary target of AcSDKP. However, in AA-injured HK-2 cells, AcSDKP paradoxically exacerbated apoptosis despite upregulating FGFR1 . Subsequent siRNA knockdown revealed that silencing FGFR1 drastically worsened apoptosis, proving that endogenous FGFR1 upregulation is a compensatory survival response. AcSDKP’s epithelial toxicity is fundamentally FGFR1 -independent, driven instead by its concurrent inhibition of the Akt survival pathway.
Conclusion
AcSDKP exerts a compartment-specific dual role in CKD. It is a potent vascular protector that halts PMT and promotes VEGF -driven endothelial repair, but acts as a pro-apoptotic stressor in severely damaged tubules. Its clinical translation necessitates early-stage intervention and optimized delivery strategies to maximize vascular benefits while mitigating epithelial toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Kidney Pathology and Immunology Laboratory, Pediatric Clinical Research Institute of Soochow University, Pediatric Clinical Medical College of Soochow University, Children's Hospital of Soochow University, Soochow, Chin…
- Pediatric Department, Suzhou Municipal Hospital & Department of Nephrology and Immunology, Children's Hospital of Soochow University, Soochow, China.
- Department of Nephrology and Immunology, Children's Hospital of Soochow University, Soochow, China.
- Electronic Information School of Wuhan University, Wuhan, China.
- Pediatric Clinical Research Institute of Soochow University, Pediatric Clinical Medical College of Soochow University, Children's Hospital of Soochow University, Soochow, China.
- Pediatric Clinical Research Institute of Soochow University, Pediatric Clinical Medical College of Soochow University, Department of Nephrology and Immunology, Children's Hospital of Soochow University, Soochow, China.
ORCID-Profile: Xiaozhong Li
Förderung
- Suzhou Key Discipline Project of Pediatric Immunology
- Key Laboratory in Science and Technology Development Project of Suzhou
Zitieren
APA
Zhu, S., Shi, L., Huang, L., Cui, N., Chen, R., Jiang, L., Zhang, A., Xu, Y., & Li, X. (2026). A dual role of AcSDKP in chronic kidney disease: Targeting pericyte-driven fibrosis and vascular repair via VEGF/FGFR1 while eliciting a compensatory FGFR1 upregulation in apoptotic tubular cells. PLOS One. https://doi.org/10.1371/journal.pone.0355409
Vancouver
Zhu S, Shi L, Huang L, Cui N, Chen R, Jiang L, et al. A dual role of AcSDKP in chronic kidney disease: Targeting pericyte-driven fibrosis and vascular repair via VEGF/FGFR1 while eliciting a compensatory FGFR1 upregulation in apoptotic tubular cells. PLOS One. 2026. doi:10.1371/journal.pone.0355409
BibTeX
@article{Zhu2026,
author = {Zhu, Shiyi and Shi, Lingli and Huang, Linlin and Cui, Ningxun and Chen, Ruyue and Jiang, Lu and Zhang, Annan and Xu, Yunyun and Li, Xiaozhong},
title = {A dual role of AcSDKP in chronic kidney disease: Targeting pericyte-driven fibrosis and vascular repair via VEGF/FGFR1 while eliciting a compensatory FGFR1 upregulation in apoptotic tubular cells},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0355409}
}
EUVIMED